What records are connected here?
- Evidence lanes
- 1
- Source years
- 3
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials3,4Evidence: Smaller human trialsGut and digestion
Apraglutide is a synthetic, long-acting analogue of glucagon-like peptide-2 (GLP-2), a gut hormone, recorded in FDA’s substance registry.3,4 It is being developed for short bowel syndrome with intestinal failure. In the randomized, placebo-controlled STARS trial of 163 patients, parenteral support volume fell by 25.5% with apraglutide and 12.5% with placebo after 24 weeks.4 No FDA approval is reported in the sources reviewed here, and apraglutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,7
| What it is | A synthetic 33-amino-acid GLP-2 analogue containing norleucine and a D-phenylalanine, according to FDA’s substance registry.3 |
|---|---|
| FDA status | Not FDA-approved. None of the sources reviewed here reports an approval of apraglutide.3,4 |
| Human evidence | One randomized, double-blind, placebo-controlled Phase 3 trial (STARS) in 163 patients with short bowel syndrome, published in 2026.4 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Apraglutide is a synthetic peptide based on GLP-2, with substitutions including norleucine and a D-phenylalanine, according to FDA’s substance registry.3
The STARS investigators describe it as a long-acting GLP-2 analogue that promotes intestinal adaptation, which may reduce dependence on parenteral support, nutrition and fluids that bypass the gut.4
STARS randomized 163 patients with short bowel syndrome and intestinal failure, 80 with a stoma and 83 with the colon still connected, to apraglutide or placebo.4
At 24 weeks, weekly parenteral support volume fell by 25.5% with apraglutide and 12.5% with placebo, and more patients cut at least one day a week of support (43.0% versus 27.5%). At 48 weeks in patients with the colon connected, the differences were not significant.4
ClinicalTrials.gov lists STARS (NCT04627025) as completed, and a further Phase 3 trial in short bowel syndrome with intestinal failure (NCT07742735) as recruiting in its August 4, 2026 record.1,2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of apraglutide by FDA.3,4
Apraglutide remains in clinical trials: a Phase 3 registration (NCT07742735) is listed as recruiting in its August 4, 2026 record.1
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list apraglutide.5
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Apraglutide is not among them.6,7
Whether it helps people whose colon is still connected over the longer term: at 48 weeks the differences from placebo in that group were not significant.4
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Apraglutide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Apraglutide are a bounded selection, not every registration or paper about Apraglutide. For the years before Apraglutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Apraglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Apraglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 163 patients, apraglutide reduced parenteral support volume more than placebo at 24 weeks. Apraglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 163 patients, apraglutide reduced parenteral support volume more than placebo at 24 weeks. Apraglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date August 4, 2026
ClinicalTrials.gov record NCT07742735↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT07742735↗Source date August 4, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05706623↗Source date July 10, 2025Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT05018286↗Source date July 2, 2025PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
8 of 8 selected trial records include at least one phase value; 8 of 8 include a status value in the retained structured contract.
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.
PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span October 24, 2024 to August 4, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07742735 at 2026-11-16T01:47:19.543Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05706623 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-10, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05018286 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06002555 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05995704 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was apraglutide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Clinical Gastroenterology and Hepatology · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026